ATE554106T1 - Antikörper für onkogene stämme von hpv und verfahren zu deren verwendung - Google Patents

Antikörper für onkogene stämme von hpv und verfahren zu deren verwendung

Info

Publication number
ATE554106T1
ATE554106T1 AT04815434T AT04815434T ATE554106T1 AT E554106 T1 ATE554106 T1 AT E554106T1 AT 04815434 T AT04815434 T AT 04815434T AT 04815434 T AT04815434 T AT 04815434T AT E554106 T1 ATE554106 T1 AT E554106T1
Authority
AT
Austria
Prior art keywords
antibodies
hpv
subject
strains
proteins
Prior art date
Application number
AT04815434T
Other languages
English (en)
Inventor
Peter Lu
Jonathan Garman
Michael Belmares
Diaz-Sarmiento Chamorro Somoza
Johannes Schweizer
Original Assignee
Arbor Vita Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arbor Vita Corp filed Critical Arbor Vita Corp
Application granted granted Critical
Publication of ATE554106T1 publication Critical patent/ATE554106T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/084—Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5755—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the uterine cervix, uterine corpus or endometrium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Oncology (AREA)
AT04815434T 2003-12-23 2004-12-23 Antikörper für onkogene stämme von hpv und verfahren zu deren verwendung ATE554106T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53237303P 2003-12-23 2003-12-23
PCT/US2004/043356 WO2005063286A1 (en) 2003-12-23 2004-12-23 Antibodies for oncogenic strains of hpv and methods of their use

Publications (1)

Publication Number Publication Date
ATE554106T1 true ATE554106T1 (de) 2012-05-15

Family

ID=34738792

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04815434T ATE554106T1 (de) 2003-12-23 2004-12-23 Antikörper für onkogene stämme von hpv und verfahren zu deren verwendung

Country Status (7)

Country Link
US (5) US7399467B2 (de)
EP (1) EP1708745B1 (de)
JP (1) JP5030594B2 (de)
AT (1) ATE554106T1 (de)
AU (1) AU2004308964B2 (de)
CA (1) CA2551560A1 (de)
WO (1) WO2005063286A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US7312041B2 (en) 2001-02-16 2007-12-25 Arbor Vita Corporation Methods of diagnosing cervical cancer
AU2004308964B2 (en) * 2003-12-23 2010-09-16 Arbor Vita Corporation Antibodies for oncogenic strains of HPV and methods of their use
US7972776B2 (en) * 2005-11-15 2011-07-05 Oncohealth Corporation Protein chips for HPV detection
US7732166B2 (en) * 2005-11-15 2010-06-08 Oncohealth Corporation Detection method for human pappilomavirus (HPV) and its application in cervical cancer
EP2024520B1 (de) * 2006-05-11 2014-03-05 Becton, Dickinson and Company Verfahren zur proteinextraktion aus zellen
US8968995B2 (en) 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
US8859218B2 (en) * 2008-06-13 2014-10-14 Oncohealth Corp. In situ detection of early stages and late stages HPV infection
AU2008269721B2 (en) 2007-05-31 2013-01-10 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Intradermal HPV peptide vaccination
AU2015213420B2 (en) * 2007-05-31 2017-02-16 Isa Pharmaceuticals B.V. HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
JP6035503B2 (ja) 2007-05-31 2016-11-30 アカデミシュ ジーケンハウス ライデン ハー．オー．デー．エン． ルムク ワクチンで使用するための、子宮頸部悪性腫瘍に浸潤するｔ細胞によって標的とされるｈｐｖエピトープ
US7838215B2 (en) * 2007-09-25 2010-11-23 Canvir, Inc. Advanced cervical cell screening methods
US9207240B2 (en) 2007-11-14 2015-12-08 Arbor Vita Corporation Method of efficient extraction of protein from cells
CN102498217A (zh) * 2009-04-20 2012-06-13 阿波维塔公司 Hpv的e6蛋白的特异性抗体及其应用
CN102449479B (zh) * 2009-05-07 2015-11-25 安科健康公司 鉴别高度或≥cin2用于人乳头瘤病毒(hpv)与hpv相关癌症的早期及晚期检测、筛检和诊断
TWI497075B (zh) * 2009-06-11 2015-08-21 Oncohealth Corp 早期及晚期人類乳突病毒感染之偵測
JP5819851B2 (ja) 2010-01-08 2015-11-24 オンコヘルス コーポレーション Ｈｐｖ関連の癌の治療及びスクリーニングのための細胞に基づいた高処理能力ｈｐｖ免疫アッセイ
US9765115B2 (en) 2011-04-01 2017-09-19 Board of Supervisors of Louisiana State University acting on behalf of the University of Louisiana at Monroe Inhibitors of metastasis, methods of generating such inhibitors and their therapeutic applications
CA2911894C (en) * 2013-05-06 2022-08-02 Bio-Rad Laboratories, Inc. Stabilization of labile analytes in reference materials
EP3015863A1 (de) * 2014-10-31 2016-05-04 Mikrogen GmbH Immunologischer Test zum Nachweis von E7-Onkoproteinen in biologischen Proben
EP3519433A1 (de) 2016-10-03 2019-08-07 Juno Therapeutics, Inc. Hpv-spezifische bindungsmoleküle
EP3692063A1 (de) 2017-10-03 2020-08-12 Juno Therapeutics, Inc. Hpv-spezifische bindungsmoleküle
EP3743436A4 (de) * 2018-01-24 2021-10-27 The Council Of The Queensland Institute Of Medical Research Hpv-immuntherapie
CN112566698A (zh) 2018-04-05 2021-03-26 朱诺治疗学股份有限公司 T细胞受体和表达该t细胞受体的工程化细胞
AU2019276162B2 (en) 2018-05-30 2025-09-25 Deutsches Krebsforschungszentrum Combined prophylactic and therapeutic vaccines
CN115925888B (zh) * 2022-11-26 2023-06-27 山西省中医药研究院（山西省中医院） 与人乳头瘤病毒hpv特异性结合的羊驼源纳米抗体及其应用
CN120390648A (zh) * 2022-12-14 2025-07-29 小马尔特·乌斯塔夫 用于靶向捕获膜蛋白的工程化的病毒样颗粒

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
EP0146654A3 (de) 1980-06-20 1986-08-20 Unilever Plc Verfahren und Vorrichtung zur Durchführung von spezifischen Bindungstesten
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5876922A (en) 1985-07-31 1999-03-02 Institute Pasteur Papillomavirus probe and a process for in vitro diagnosis of papillomavirus infections
FR2586428B1 (fr) * 1985-08-26 1988-11-25 Pasteur Institut Polypeptides et anticorps, caracteristiques du papillomavirus et leurs applications au diagnostic in vitro, a la prevention et/ou la lutte contre des infections a papillomavirus
DE3779175D1 (de) 1986-03-21 1992-06-25 Pasteur Institut Bestimmte, von einem papillomavirus-genom abgeleitete dns-sequenzen, deren anwendungen fuer in vitro-diagnostische zwecke und die herstellung von antigenzusammensetzungen.
US4777239A (en) * 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
US5204061A (en) 1987-10-08 1993-04-20 Becton, Dickinson And Company Depositing a binder on a solid support
US5180806A (en) * 1988-05-16 1993-01-19 The Scripps Research Institute Polypeptides and compositions of human papillomavirus latent proteins, diagnostic systems and methods
EP0737750B1 (de) 1989-03-21 2003-05-14 Vical, Inc. Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
US5814460A (en) * 1990-02-14 1998-09-29 Diatide, Inc. Method for generating and screening useful peptides
US5753233A (en) 1990-05-10 1998-05-19 Behring Diagnostics Gmbh Seroreactive epitopes on proteins of human papilloma-virus (HPV) 18
DE4015044A1 (de) 1990-05-10 1991-11-14 Behringwerke Ag Seroreaktive epitope auf proteinen des menschlichen papillomavirus (hpv) 18
US5932412A (en) * 1990-05-11 1999-08-03 Euro-Diagnostica Ab Synthetic peptides in human papillomaviruses 1, 5, 6, 8, 11, 16, 18, 31, 33 and 56, useful in immunoassay for diagnostic purposes
US5604105B1 (en) 1990-10-12 1999-08-24 Spectral Diagnostics Inc Method and device for diagnosingand distinguishing chest pain in early onset thereof
FR2670797A1 (fr) 1990-12-20 1992-06-26 Pasteur Institut Sequences d'adn determinees derivees du genome du papillomavirus hpv39, application de ces sequences au diagnostic in vitro d'infection par ce papillomavirus, et a la production de composition immunogene.
ES2193133T3 (es) * 1991-07-13 2003-11-01 Dade Behring Marburg Gmbh Uso de peptidos derivados de los genes e6 y e7 de hpv-16 para fines.
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
US5571680A (en) 1994-01-21 1996-11-05 Beckman Instruments, Inc. Homogeneous immunoassays and enzyme based assays of analytes using capillary electrophoresis
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6352842B1 (en) 1995-12-07 2002-03-05 Diversa Corporation Exonucease-mediated gene assembly in directed evolution
EP0871747A1 (de) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunstimulierung vermittelt durch genmodifizierte dendritische zellen
US5643752A (en) 1996-01-18 1997-07-01 Incyte Pharmaceuticals, Inc. Tissue inhibitor of metalloproteinases
ATE309366T1 (de) 1996-02-22 2005-11-15 Merck & Co Inc Synthetische hiv-gene
WO1997048370A2 (en) 1996-06-21 1997-12-24 Merck & Co., Inc. Vaccines comprising synthetic genes
CA2280195A1 (en) 1997-02-07 1998-08-13 Merck & Co., Inc. Synthetic hiv gag genes
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
EP1104306B1 (de) 1998-08-10 2006-01-11 Antigenics Inc. Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
US6492143B1 (en) 1998-12-17 2002-12-10 The John Hopkins University Olfactory receptor expression libraries and methods of making and using them
DE19901008A1 (de) * 1999-01-13 2000-07-20 Deutsches Krebsforsch Peptide zur Inhibierung von HPV E6-Proteinen
CA2361005A1 (en) 1999-01-25 2000-07-27 Yale University Novel odorant receptors in drosophila
EP2058327A3 (de) 1999-02-25 2010-08-25 The Trustees of Columbia University in the City of New York Gene zur Kodierung von Insektenduftstoffrezeptoren und ihre Verwendung
CN1227030C (zh) 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
US6242266B1 (en) 1999-04-30 2001-06-05 Agilent Technologies Inc. Preparation of biopolymer arrays
CA2380000A1 (en) 1999-07-20 2001-01-25 The Regents Of The University Of California Odorant receptors
US6440696B1 (en) 1999-07-28 2002-08-27 New England Medical Center E6 targeted protein (E6TP1)
GB0017990D0 (en) 2000-07-21 2000-09-13 Glaxo Group Ltd Papilloma virus sequences
GB0018140D0 (en) * 2000-07-24 2000-09-13 Medical Res Council Screening for abnormalities
WO2002007751A1 (en) 2000-07-25 2002-01-31 Axcell Biosciences Corporation Identification and isolation of novel polypeptides having pdz domains and methods of using same
US6346416B1 (en) 2000-08-29 2002-02-12 Isis Pharmaceuticals, Inc. Antisense inhibition of HPK/GCK-like kinase expression
US8613907B2 (en) * 2000-10-12 2013-12-24 University Of Rochester Compositions that inhibit proliferation of cancer cells
US7312041B2 (en) 2001-02-16 2007-12-25 Arbor Vita Corporation Methods of diagnosing cervical cancer
US20040229298A1 (en) * 2000-11-11 2004-11-18 Lu Peter S. Methods and compositions for treating cervical cancer
ES2284559T3 (es) 2001-03-23 2007-11-16 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Genes y proteinas e6 y e7 modificados del vph utiles como vacuna.
WO2002077012A2 (en) * 2001-03-23 2002-10-03 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Human papilloma virus immunoreative peptides
TWI229132B (en) * 2001-05-04 2005-03-11 King Car Food Ind Co Ltd Method and detector for identifying subtypes of human papilloma viruses
AU2002321903A1 (en) 2001-08-03 2003-02-24 Arbor Vita Corporation Molecular interactions in cells
WO2003018055A1 (en) 2001-08-23 2003-03-06 Merck & Co., Inc. Vaccine using papilloma virus e proteins delivered by viral vector
EP1537415B1 (de) * 2002-09-09 2008-12-17 Arbor Vita Corporation Verfahren zur diagnose von gebärmutterhalskrebs
AU2004308964B2 (en) 2003-12-23 2010-09-16 Arbor Vita Corporation Antibodies for oncogenic strains of HPV and methods of their use
US20130017572A1 (en) 2009-04-30 2013-01-17 Lu Peter S Codon modified polynucleotide sequences for enhanced expression in a host system

Also Published As

Publication number Publication date
AU2004308964A1 (en) 2005-07-14
US9611315B2 (en) 2017-04-04
WO2005063286A1 (en) 2005-07-14
US20150093742A1 (en) 2015-04-02
US20090047660A1 (en) 2009-02-19
EP1708745B1 (de) 2012-04-18
JP2007522108A (ja) 2007-08-09
EP1708745A1 (de) 2006-10-11
US20050142541A1 (en) 2005-06-30
CA2551560A1 (en) 2005-07-14
US20100209904A1 (en) 2010-08-19
JP5030594B2 (ja) 2012-09-19
AU2004308964B2 (en) 2010-09-16
US7399467B2 (en) 2008-07-15
US20120164629A1 (en) 2012-06-28
EP1708745A4 (de) 2007-12-19

Similar Documents

Publication Publication Date Title
EP1708745A4 (de) Antikörper für onkogene stämme von hpv und verfahren zu deren verwendung
DE59903915D1 (de) Verfahren zur frühen diagnose von carcinomen
DE60041839D1 (de) Auto-Antikörper gegen Annexin-Proteine als Marker für Lungenkrebs
DE50204883D1 (de) Verfahren zum qualitativen und/oder quantitativen nachweis von zellen
ATE401342T1 (de) Verfahren und materialien zum nachweis und zur messung von durch freie radikale verursachten schäden
DE60315715D1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
DE60129239D1 (de) Kit und verfahren zur bestimmung von protein esm-1
DE60325382D1 (de) Verfahren zur diagnose von gebärmutterhalskrebs
ATE529533T1 (de) Verfahren zum nachweis von analyten in einer probe
RU2000114841A (ru) Антитела против фосфорилированного vasp (стимулированного вазодилататором фосфопротеина), гибридомные клетки для их получения и их применение
WO2005019831B1 (en) Methods for reducing complexity of a sample using small epitope antibodies
JP2005538360A5 (de)
ATE397215T1 (de) Entstörung von immunoassays durch substanzen, die aus den framework-regionen von antikörpern abgeleitet sind
ATE392621T1 (de) Verfahren zur quantifizierung von glykiertem protein
DE602006013333D1 (de) Kit und verfahren zum nachweis von urothelkarzinom
ATE288589T1 (de) Verfahren zur analyse von proteinen
ATE433463T1 (de) Monospezifische antikörper gegen fibrinogen und fibrinopeptide b
ATE383418T1 (de) Verfahren und zusammensetzungen zur bestimmung glycierter proteine
DE60228952D1 (de) Nachweis von Legionella durch ein PCR und FRET verwendendes Verfahren
EP1476757A4 (de) Verfahren und kit zur krebsvorhersage
ATE535546T1 (de) Humane monoklonale antikörper, die spezifisch an ifg-ii binden
DE50212790D1 (de) Verfahren zum nachweis von blutzell-antigenen und gegen diese gerichtete antikörper
DE602004001994D1 (de) Verwendung des proteins masp als marker für kolorektale karzinome
ATE534037T1 (de) Verwendung des proteins asc als marker für brustkrebs
ATE532796T1 (de) Immunassays zur spezifischen bestimmung von scca- isoformen